Which has preferable valuation and earnings, OTLK or ALT?

Oncobiologics has higher revenue and earnings than Altimmune. Altimmune is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oncobiologics $1.35M 119.02 -$62.42M -$0.77 N/A Altimmune $40K 15,902.01 -$88.09M -$0.78 N/A

Is OTLK or ALT more profitable?

Oncobiologics has a net margin of 0.00% compared to Altimmune's net margin of -214,860.98%. Oncobiologics' return on equity of 0.00% beat Altimmune's return on equity. Company Net Margins Return on Equity Return on Assets Oncobiologics N/A N/A -254.82% Altimmune -214,860.98% -31.41% -26.96%

Does the media prefer OTLK or ALT?

In the previous week, Oncobiologics had 4 more articles in the media than Altimmune. MarketBeat recorded 7 mentions for Oncobiologics and 3 mentions for Altimmune. Altimmune's average media sentiment score of 1.17 beat Oncobiologics' score of 0.36 indicating that Altimmune is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oncobiologics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Altimmune 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is OTLK or VALN more profitable?

Oncobiologics has a net margin of 0.00% compared to Valneva's net margin of -110.33%. Oncobiologics' return on equity of 0.00% beat Valneva's return on equity. Company Net Margins Return on Equity Return on Assets Oncobiologics N/A N/A -254.82% Valneva -110.33% -153.20% -39.50%

Does the media refer more to OTLK or VALN?

In the previous week, Oncobiologics had 4 more articles in the media than Valneva. MarketBeat recorded 7 mentions for Oncobiologics and 3 mentions for Valneva. Valneva's average media sentiment score of 0.38 beat Oncobiologics' score of 0.36 indicating that Valneva is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oncobiologics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Valneva 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is OTLK or STTK more profitable?

Oncobiologics' return on equity of 0.00% beat Shattuck Labs' return on equity. Company Net Margins Return on Equity Return on Assets Oncobiologics N/A N/A -254.82% Shattuck Labs N/A -43.57% -40.90%

Does the media prefer OTLK or STTK?

In the previous week, Oncobiologics had 2 more articles in the media than Shattuck Labs. MarketBeat recorded 7 mentions for Oncobiologics and 5 mentions for Shattuck Labs. Shattuck Labs' average media sentiment score of 1.41 beat Oncobiologics' score of 0.36 indicating that Shattuck Labs is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oncobiologics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Shattuck Labs 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is OTLK or ALLO more profitable?

Oncobiologics' return on equity of 0.00% beat Allogene Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Oncobiologics N/A N/A -254.82% Allogene Therapeutics N/A -50.04% -36.74%

Does the media prefer OTLK or ALLO?

In the previous week, Oncobiologics and Oncobiologics both had 7 articles in the media. Allogene Therapeutics' average media sentiment score of 0.55 beat Oncobiologics' score of 0.36 indicating that Allogene Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oncobiologics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Allogene Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is OTLK or MPLT more profitable?

Oncobiologics' return on equity of 0.00% beat Maplight Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Oncobiologics N/A N/A -254.82% Maplight Therapeutics N/A -98.60% -60.33%

Does the media prefer OTLK or MPLT?

In the previous week, Oncobiologics had 5 more articles in the media than Maplight Therapeutics. MarketBeat recorded 7 mentions for Oncobiologics and 2 mentions for Maplight Therapeutics. Maplight Therapeutics' average media sentiment score of 0.93 beat Oncobiologics' score of 0.36 indicating that Maplight Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oncobiologics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Maplight Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Oncobiologics (OTLK) Competitors

$0.66 0.00 (-0.18%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$0.66 0.00 (-0.45%)

As of 09/11/2026 07:53 PM Eastern

Compare

OTLK vs. ALT, VALN, STTK, ALLO, and MPLT

Should you buy Oncobiologics stock or one of its competitors? Oncobiologics's main competitors and comparable companies include Altimmune (ALT), Valneva (VALN), Shattuck Labs (STTK), Allogene Therapeutics (ALLO), and Maplight Therapeutics (MPLT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Oncobiologics compare to Altimmune?

Oncobiologics (NASDAQ:OTLK) and Altimmune (NASDAQ:ALT) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.

Oncobiologics has higher revenue and earnings than Altimmune. Altimmune is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncobiologics	$1.35M	119.02	-$62.42M	-$0.77	N/A
Altimmune	$40K	15,902.01	-$88.09M	-$0.78	N/A

In the previous week, Oncobiologics had 4 more articles in the media than Altimmune. MarketBeat recorded 7 mentions for Oncobiologics and 3 mentions for Altimmune. Altimmune's average media sentiment score of 1.17 beat Oncobiologics' score of 0.36 indicating that Altimmune is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oncobiologics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Altimmune	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

11.2% of Oncobiologics shares are owned by institutional investors. Comparatively, 78.1% of Altimmune shares are owned by institutional investors. 1.8% of Oncobiologics shares are owned by insiders. Comparatively, 1.6% of Altimmune shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Oncobiologics has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market. Comparatively, Altimmune has a beta of 0.18, indicating that its share price is 82% less volatile than the broader market.

Oncobiologics currently has a consensus target price of $5.20, indicating a potential upside of 687.88%. Altimmune has a consensus target price of $14.33, indicating a potential upside of 338.33%. Given Oncobiologics' higher possible upside, research analysts plainly believe Oncobiologics is more favorable than Altimmune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncobiologics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Altimmune	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Oncobiologics has a net margin of 0.00% compared to Altimmune's net margin of -214,860.98%. Oncobiologics' return on equity of 0.00% beat Altimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncobiologics	N/A	N/A	-254.82%
Altimmune	-214,860.98%	-31.41%	-26.96%

Summary

Oncobiologics beats Altimmune on 10 of the 16 factors compared between the two stocks.

How does Oncobiologics compare to Valneva?

Oncobiologics (NASDAQ:OTLK) and Valneva (NASDAQ:VALN) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, media sentiment, valuation, dividends, risk and profitability.

Oncobiologics has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market. Comparatively, Valneva has a beta of 1.67, indicating that its stock price is 67% more volatile than the broader market.

Oncobiologics has a net margin of 0.00% compared to Valneva's net margin of -110.33%. Oncobiologics' return on equity of 0.00% beat Valneva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncobiologics	N/A	N/A	-254.82%
Valneva	-110.33%	-153.20%	-39.50%

Oncobiologics currently has a consensus target price of $5.20, suggesting a potential upside of 687.88%. Valneva has a consensus target price of $9.30, suggesting a potential upside of 39.64%. Given Oncobiologics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Oncobiologics is more favorable than Valneva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncobiologics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Valneva	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

Oncobiologics has higher earnings, but lower revenue than Valneva. Valneva is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncobiologics	$1.35M	119.02	-$62.42M	-$0.77	N/A
Valneva	$197.56M	3.20	-$130.33M	-$2.11	N/A

In the previous week, Oncobiologics had 4 more articles in the media than Valneva. MarketBeat recorded 7 mentions for Oncobiologics and 3 mentions for Valneva. Valneva's average media sentiment score of 0.38 beat Oncobiologics' score of 0.36 indicating that Valneva is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oncobiologics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Valneva	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

11.2% of Oncobiologics shares are owned by institutional investors. Comparatively, 11.4% of Valneva shares are owned by institutional investors. 1.8% of Oncobiologics shares are owned by insiders. Comparatively, 14.9% of Valneva shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Oncobiologics beats Valneva on 10 of the 16 factors compared between the two stocks.

How does Oncobiologics compare to Shattuck Labs?

Oncobiologics (NASDAQ:OTLK) and Shattuck Labs (NASDAQ:STTK) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

Oncobiologics' return on equity of 0.00% beat Shattuck Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncobiologics	N/A	N/A	-254.82%
Shattuck Labs	N/A	-43.57%	-40.90%

Oncobiologics has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market. Comparatively, Shattuck Labs has a beta of 1.09, suggesting that its share price is 9% more volatile than the broader market.

11.2% of Oncobiologics shares are owned by institutional investors. Comparatively, 58.7% of Shattuck Labs shares are owned by institutional investors. 1.8% of Oncobiologics shares are owned by company insiders. Comparatively, 8.8% of Shattuck Labs shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Shattuck Labs has lower revenue, but higher earnings than Oncobiologics. Shattuck Labs is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncobiologics	$1.35M	119.02	-$62.42M	-$0.77	N/A
Shattuck Labs	$1M	622.23	-$48.81M	-$0.51	N/A

In the previous week, Oncobiologics had 2 more articles in the media than Shattuck Labs. MarketBeat recorded 7 mentions for Oncobiologics and 5 mentions for Shattuck Labs. Shattuck Labs' average media sentiment score of 1.41 beat Oncobiologics' score of 0.36 indicating that Shattuck Labs is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oncobiologics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Shattuck Labs	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oncobiologics currently has a consensus price target of $5.20, suggesting a potential upside of 687.88%. Shattuck Labs has a consensus price target of $12.78, suggesting a potential upside of 106.09%. Given Oncobiologics' higher possible upside, research analysts plainly believe Oncobiologics is more favorable than Shattuck Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncobiologics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Shattuck Labs beats Oncobiologics on 11 of the 16 factors compared between the two stocks.

How does Oncobiologics compare to Allogene Therapeutics?

Oncobiologics (NASDAQ:OTLK) and Allogene Therapeutics (NASDAQ:ALLO) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings.

11.2% of Oncobiologics shares are held by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are held by institutional investors. 1.8% of Oncobiologics shares are held by insiders. Comparatively, 13.2% of Allogene Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Oncobiologics has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market. Comparatively, Allogene Therapeutics has a beta of 0.47, suggesting that its stock price is 53% less volatile than the broader market.

Oncobiologics currently has a consensus target price of $5.20, indicating a potential upside of 687.88%. Allogene Therapeutics has a consensus target price of $8.30, indicating a potential upside of 366.29%. Given Oncobiologics' higher possible upside, analysts clearly believe Oncobiologics is more favorable than Allogene Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncobiologics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

In the previous week, Oncobiologics and Oncobiologics both had 7 articles in the media. Allogene Therapeutics' average media sentiment score of 0.55 beat Oncobiologics' score of 0.36 indicating that Allogene Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oncobiologics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Allogene Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oncobiologics has higher revenue and earnings than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncobiologics	$1.35M	119.02	-$62.42M	-$0.77	N/A
Allogene Therapeutics	$20K	30,748.61	-$190.89M	-$0.67	N/A

Oncobiologics' return on equity of 0.00% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncobiologics	N/A	N/A	-254.82%
Allogene Therapeutics	N/A	-50.04%	-36.74%

Summary

Allogene Therapeutics beats Oncobiologics on 9 of the 15 factors compared between the two stocks.

How does Oncobiologics compare to Maplight Therapeutics?

Oncobiologics (NASDAQ:OTLK) and Maplight Therapeutics (NASDAQ:MPLT) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, valuation, earnings, analyst recommendations, media sentiment, risk and institutional ownership.

Oncobiologics' return on equity of 0.00% beat Maplight Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncobiologics	N/A	N/A	-254.82%
Maplight Therapeutics	N/A	-98.60%	-60.33%

Oncobiologics has higher revenue and earnings than Maplight Therapeutics. Oncobiologics is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncobiologics	$1.35M	119.02	-$62.42M	-$0.77	N/A
Maplight Therapeutics	N/A	N/A	-$161.15M	-$42.31	N/A

11.2% of Oncobiologics shares are owned by institutional investors. 1.8% of Oncobiologics shares are owned by insiders. Comparatively, 3.8% of Maplight Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Oncobiologics had 5 more articles in the media than Maplight Therapeutics. MarketBeat recorded 7 mentions for Oncobiologics and 2 mentions for Maplight Therapeutics. Maplight Therapeutics' average media sentiment score of 0.93 beat Oncobiologics' score of 0.36 indicating that Maplight Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oncobiologics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Maplight Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oncobiologics presently has a consensus price target of $5.20, indicating a potential upside of 687.88%. Maplight Therapeutics has a consensus price target of $29.50, indicating a potential upside of 126.92%. Given Oncobiologics' higher probable upside, analysts plainly believe Oncobiologics is more favorable than Maplight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncobiologics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Maplight Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	4 Strong Buy rating(s)	2.94

Summary

Oncobiologics and Maplight Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

Get Oncobiologics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OTLK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OTLK vs. The Competition

Export

Metric	Oncobiologics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$160.68M	$3.85B	$7.16B	$12.85B
Dividend Yield	N/A	3.65%	2.57%	11.72%
P/E Ratio	-0.86	14.18	274.94	25.36
Price / Sales	119.02	1,374.96	685.43	116.41
Price / Cash	N/A	106.50	76.65	51.52
Price / Book	-1.10	15.12	10.33	6.20
Net Income	-$62.42M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-0.98%	-4.34%	-3.32%	-2.35%
1 Month Performance	-25.74%	0.54%	-0.53%	-3.23%
1 Year Performance	-36.54%	40.74%	23.51%	8.79%

Oncobiologics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OTLK Oncobiologics	3.378 of 5 stars	$0.66 -0.2%	$5.20 +687.9%	-36.5%	$160.68M	$1.35M	N/A	20	Short Interest Increase
ALT Altimmune	2.5267 of 5 stars	$3.28 -0.5%	$14.33 +337.7%	-10.2%	$637.05M	$40K	N/A	50
VALN Valneva	1.8842 of 5 stars	$6.69 flat	$9.30 +39.0%	-25.5%	$634.81M	$197.56M	N/A	700
STTK Shattuck Labs	3.7688 of 5 stars	$6.28 +2.0%	$12.78 +103.6%	+222.9%	$630.16M	$1M	N/A	100	Positive News
ALLO Allogene Therapeutics	1.9485 of 5 stars	$1.81 +2.6%	$8.30 +359.8%	+57.5%	$620.16M	$20K	N/A	310	Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OTLK) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oncobiologics (OTLK) Competitors

OTLK vs. ALT, VALN, STTK, ALLO, and MPLT

How does Oncobiologics compare to Altimmune?

Summary

How does Oncobiologics compare to Valneva?

Summary

How does Oncobiologics compare to Shattuck Labs?

Summary

How does Oncobiologics compare to Allogene Therapeutics?

Summary

How does Oncobiologics compare to Maplight Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OTLK vs. The Competition

Oncobiologics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oncobiologics (OTLK) Competitors

OTLK vs. ALT, VALN, STTK, ALLO, and MPLT

How does Oncobiologics compare to Altimmune?

Which has preferable valuation and earnings, OTLK or ALT?

Does the media prefer OTLK or ALT?

Do insiders & institutionals hold more shares of OTLK or ALT?

Which has more volatility and risk, OTLK or ALT?

Do analysts prefer OTLK or ALT?

Is OTLK or ALT more profitable?

Summary

How does Oncobiologics compare to Valneva?

Which has more risk & volatility, OTLK or VALN?

Is OTLK or VALN more profitable?

Do analysts recommend OTLK or VALN?

Which has preferable earnings and valuation, OTLK or VALN?

Does the media refer more to OTLK or VALN?

Do insiders & institutionals have more ownership in OTLK or VALN?

Summary

How does Oncobiologics compare to Shattuck Labs?

Is OTLK or STTK more profitable?

Which has more risk & volatility, OTLK or STTK?

Do institutionals and insiders hold more shares of OTLK or STTK?

Which has better valuation & earnings, OTLK or STTK?

Does the media prefer OTLK or STTK?

Do analysts prefer OTLK or STTK?

Summary

How does Oncobiologics compare to Allogene Therapeutics?

Do insiders and institutionals have more ownership in OTLK or ALLO?

Which has more risk and volatility, OTLK or ALLO?

Do analysts prefer OTLK or ALLO?

Does the media prefer OTLK or ALLO?

Which has better valuation & earnings, OTLK or ALLO?

Is OTLK or ALLO more profitable?

Summary

How does Oncobiologics compare to Maplight Therapeutics?

Is OTLK or MPLT more profitable?

Which has higher valuation & earnings, OTLK or MPLT?

Do insiders and institutionals believe in OTLK or MPLT?

Does the media prefer OTLK or MPLT?

Do analysts recommend OTLK or MPLT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OTLK vs. The Competition

Oncobiologics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools